Quality Biological & JPT Announce Distribution and Marketing Agreement
News Sep 16, 2005
JPT Peptide Technologies GmbH and Quality Biological, Inc. (QBI) have announced the start of a non-exclusive distribution and marketing agreement for the USA.
Within the scope of this agreement, the parties join forces to better serve customers in the US.
This cooperation will enhance the numerous marketing activities underway and accelerate customer order processing with JPT.
"I am delighted that we could win Quality Biological as distributor for our peptide-based products and services in America,” stated Peter-Paul Henze, JPT's Director of Sales and Marketing, who heads the US office of JPT in Springfield, VA.
“They are part of the Mid-Atlantic scientific community; the scientists trust them and have relied on their products and support for decades.”
“QBI, in turn, knows us and has helped process our highly explanation-prone products for selected customers for some time now.”
“I am pleased that we can now offer the ease-of-mind they guarantee to all of our American customers."
"JPT brings a wealth of experience and some very cutting-edge technologies to the table," says Sol Graham, President and CEO, of Quality Biological, Inc.
"People think that peptides are a simple commodity, but our demanding clientele knows better and simply cannot afford to lose time or waste biological material, therefore we are pleased to partner with an innovative company which values its customers and provides quality products and services to the research community."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE